10 Aug, 2020 RNAi Roundtable: Lumasiran, in Development for the Treatment of Primary Hyperoxaluria Type 1

On August 10, 2020, we hosted an online RNAi Roundtable to review progress with lumasiran, an RNAi therapeutic in development for the treatment of primary hyperoxaluria type 1.

Access the replay
View the presentation
Read the transcript

Pritesh Gandhi, PharmD.
Vice President & General Manager, Lumasiran

Michael J.G. Somers, M.D.
Associate Chief and Gunnar B. Stickler Chair in Pediatric Nephrology, Division of Nephrology and Medical Director, Renal Dialysis Unit, Boston Children’s Hospital; Associate Professor of Pediatrics, Harvard Medical School; President, American Society of Pediatric Nephrology

Tracy McGregor, M.D.
Senior Director, Clinical Research